RAD51 and myelodysplastic syndrome: It was found that the RAD51 polymorphism rs1801320 is associated with an elevated risk of breast [20–22] and triple-negative breast cancer [23] and ovarian [24, 25], endometrial [26–28], colorectal [9, 29, 30], gastric [31], and head and neck cancer [32, 33] and myelodysplastic syndrome [34], as well as keratoconus and Fuchs endothelial corneal dystrophy [35].